|
Promising Research in Early Detection of Mesothelioma
New research may result in better diagnosis for patients diagnosed in the
early stages of mesothelioma.
(PRWEB) January 9, 2006 -- Mesothelioma, once a rare cancer, has become more
prevalent in the past 50 years. The incidence of this aggressive disease, which
has no cure, is expected to rise through 2015. Until recently, mesothelioma
was considered universally fatal. Patients treated with the best available
therapy have survived 13 to 25 months in some studies, and with only supportive
care the median survival is about 9 months. Studies investigating the diagnosis
of mesothelioma have recently reported promising results, which may help reverse
this tragic trend.
If caught before spreading beyond the lungs, there is
a much greater chance of successfully treating the disease. Once mesothelioma
has spread, the disease quickly overcomes its victim. With earlier detection,
current treatments would be more effective, more aggressive treatment could be
developed and life expectancy could rise dramatically.
One of the
challenges of treatment for mesothelioma patients is the inability to detect the
aggressive cancer in its early stages. Unfortunately, mesothelioma is very
challenging to diagnose until the advanced stages. Because the onset of disease
is delayed for as much as 30 years beyond exposure, symptoms are vague and the
diagnostic tools are not efficient or specific, many cases are not diagnosed
until the disease is advanced.
To date, screening through serial chest
x-rays and pulmonary function testing has not been effective in detecting the
disease in its earlier stages. While some asbestos related disease has been
detected, these methods cannot differentiate between mesothelioma and benign
lung disorders. Computer tomography (CT) can detect even small tumors, but also
does not distinguish between malignant lesions and benign lung changes. Thus,
the stumbling block to early diagnosis is distinguishing early stage cancer from
other lung problems.
Biomarkers, or naturally occurring chemicals that
can be detected in the blood have been linked to many specific cancers. Studies
have shown a link between the substance TPA and mesothelioma, but this
correlation had not yet been proven. Ca 125, a known marker for ovarian cancer
has also shown promising but unconfirmed results in detecting early stage
mesothelioma.
According to a recent article published in the December
2005 New England Journal of Medicine, a recent study of the protein osteopontin
produced encouraging results. Comparing patients diagnosed with mesothelioma,
patients exposed to asbestos but disease free and healthy control subjects,
revealed clear differences in the patients with malignant disease. Although more
research is needed to confirm the accuracy of this investigation, a strong
correlation between osteopontin levels and mesothelioma was found.
A
significantly higher concentration of osteopontin was detected in patients with
diagnosed cases of mesothelioma compared to subjects with asbestos exposure.
When compared, the levels of osteopontin were not significantly different in
unexposed control subjects versus those subjects exposed to asbestos. Nearly 78%
of mesothelioma patients showed elevated osteopontin levels. Levels were
elevated in both patients with early stage disease (Stage I) and advanced
disease. In over 85% of cases, osteopontin levels differentiated patients with
mesothelioma versus benign lung conditions.
Definitive detection of
mesothelioma in the earlier stages makes surgical removal of tumors possible
before the disease has had a chance to spread. Once spread occurs, the
effectiveness of surgical treatment drops dramatically. In end–stage disease,
surgery is simply a palliative measure to improve breathing capability with
little of no curative value.
While it is not clear that this information
will lead to longer survival, we do know that the earlier treatment can begin,
the better chance for a prolonged life expectancy and with time, hopefully a
cure.
Visit http://www.asbestos-post.com for current asbestos and
mesothelioma news as well as a dedicated asbestos RSS feed.
© 2005 - 2008 H. Vanoy Barton, all rights reserved.
|
|
|